Page last updated: 2024-10-17

bupropion and Basal Ganglia Diseases

bupropion has been researched along with Basal Ganglia Diseases in 2 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guo, MY1
Etminan, M1
Procyshyn, RM1
Kim, DD1
Samii, A1
Kezouh, A1
Carleton, BC1
Szuba, MP1
Leuchter, AF1

Other Studies

2 other studies available for bupropion and Basal Ganglia Diseases

ArticleYear
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:4

    Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxeti

2018
Falling backward in two elderly patients taking bupropion.
    The Journal of clinical psychiatry, 1992, Volume: 53, Issue:5

    Topics: Age Factors; Aged; Basal Ganglia Diseases; Bupropion; Depressive Disorder; Dyskinesia, Drug-Induced;

1992